23020-18-0

Basic information

• Product Name: (1S)-2α-Phenylcyclopropane-1α-carboxylic acid
• Synonyms: (1S)-2α-Phenylcyclopropane-1α-carboxylic acid;(1S,2R)-2-Phenylcyclopropanecarboxylic acid;(1S,2R)-2-phenylcyclopropanecarboxylic acid (1S,2R)-2-(pyridin-4-yl)cyclopropanecarboxylic acid;(1S)-2α-Phenylcyclopropane-1&alpha
• CAS NO: 23020-18-0
• Molecular Formula: C₁₀H₁₀O₂
• Molecular Weight: 162.19
• Mol File: 23020-18-0.mol
• Article Data: 19

Chemical Properties

• Melting Point: 83-84 °C
• Boiling Point: 135-140 °C(Press: 0.04 Torr)
• Appearance: /
• Density: 1.250±0.06 g/cm3(Predicted)
• PKA: 4.57±0.10(Predicted)
• CAS DataBase Reference: (1S)-2α-Phenylcyclopropane-1α-carboxylic acid(CAS DataBase Reference)
• NIST Chemistry Reference: (1S)-2α-Phenylcyclopropane-1α-carboxylic acid(23020-18-0)
• EPA Substance Registry System: (1S)-2α-Phenylcyclopropane-1α-carboxylic acid(23020-18-0)

Safety Data

• Hazardous Substances Data: 23020-18-0(Hazardous Substances Data)

Usage

Description

(1S)-2α-Phenylcyclopropane-1α-carboxylic acid, also known as PCC, is a chiral compound characterized by a cyclopropane ring and a carboxylic acid functional group. It is a synthetic compound with potential pharmaceutical applications, particularly as an anti-inflammatory agent.
Used in Pharmaceutical Industry:
(1S)-2α-Phenylcyclopropane-1α-carboxylic acid is used as an anti-inflammatory agent for its ability to inhibit the production of pro-inflammatory mediators, making it a promising candidate for the development of new drugs for the treatment of inflammatory conditions. Its unique structure and properties make it an interesting target for further research and potential therapeutic use.

Upstream product

• 110-82-7 cyclohexane 
• 84564-98-7 peracide phenyl-2-cyclopropane carboxyloque cis 
• 124-38-9 carbon dioxide 
• 36617-02-4 1-bromo-2-phenylcyclopropane 
• 946-38-3 ethyl 2-phenylcyclopropylcarboxylate 
• 5685-38-1 2-phenyl-cyclopropanecarboxylic acid 
• 201230-82-2 carbon monoxide 
• 3234-51-3 1,1-dibromo-2-phenylcyclopropane 
• 100-42-5 styrene 
• 75-47-8 iodoform 
• 140-10-3 cis-cinnamic acid 
• 5617-74-3 cis-1,2-cyclopropanedicarboxylic acid anhydride 
• 1078-58-6 diphenylzinc 
• 946-38-3 cis-1-ethoxycarbonyl-2-phenylcyclopropane 

Downstream Products

• 17955-08-7 ((1S,2S)-2-Vinyl-cyclopropyl)-benzene 
• 1265913-13-0 ((1S,5R)-5-(3-methoxyphenyl)-2-azabicyclo[3.3.1]nonan-2-yl)-((1'S,2'R)-2-phenylcyclopropyl)methanone 
• 1265913-11-8 ((1R,5S)-5-(3-methoxyphenyl)-2-azabicyclo[3.3.1]nonan-2-yl)-((1'S,2'R)-2-phenylcyclopropyl)methanone 
• 1265913-27-6 (1R,5S)-5-(3-methoxyphenyl)-2-(((1'S,2'R)-2-phenylcyclopropyl)methyl)-2-azabicyclo[3.3.1]nonane 
• 1265913-28-7 (1S,5R)-5-(3-methoxyphenyl)-2-(((1'S,2'R)-2-phenylcyclopropyl)methyl)-2-azabicyclo[3.3.1]nonane 
• 1265968-41-9 3-((1R,5S)-2-(((1'S,2'R)-2-phenylcyclopropyl)methyl)-2-azabicyclo[3.3.1]nonan-5-yl)phenol 
• 1265968-42-0 3-((1S,5R)-2-(((1'S,2'R)-2-phenylcyclopropyl)methyl)-2-azabicyclo[3.3.1]nonan-5-yl)phenol 
• 42916-17-6 ((1R,4aS)-7-isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthren-1-yl)methanaminium (1R,2S)-2-phenylcyclopropane-1-carboxylate 
• 1265913-09-4 ((1S,5R)-5-(3-methoxyphenyl)-2-azabicyclo[3.3.1]nonan-2-yl)-((1'R,2'S)-2-phenylcyclopropyl)methanone 
• 1265913-16-3 ((1R,5S)-5-(3-methoxyphenyl)-2-azabicyclo[3.3.1]nonan-2-yl)-((1'R,2'S)-2-phenylcyclopropyl)methanone 
• 1265913-25-4 (1S,5R)-5-(3-methoxyphenyl)-2-(((1'R,2'S)-2-phenylcyclopropyl)methyl)-2-azabicyclo[3.3.1]nonane 
• 1265913-30-1 (1R,5S)-5-(3-methoxyphenyl)-2-(((1'R,2'S)-2-phenylcyclopropyl)methyl)-2-azabicyclo[3.3.1]nonane 
• 1265968-40-8 3-((1S,5R)-2-(((1'R,2'S)-2-phenylcyclopropyl)methyl)-2-azabicyclo[3.3.1]nonan-5-yl)phenol 
• 1265968-43-1 3-((1R,5S)-2-(((1'R,2'S)-2-phenylcyclopropyl)methyl)-2-azabicyclo[3.3.1]nonan-5-yl)phenol 

Relevant articles and documents

Stereoselective Functionalization of Racemic Cyclopropylzinc Reagents via Enantiodivergent Relay Coupling

Efficient construction of optically pure molecules from readily available starting materials in a simple manner is an ongoing goal in asymmetric synthesis. As a straightforward route, transition-metal-catalyzed enantioconvergent coupling between widely available secondary alkyl electrophiles and organometallic nucleophiles has emerged as a powerful strategy to construct chiral center(s). However, the scope of racemic secondary alkylmetallic nucleophiles for this coupling remains limited in specific substrates because of the difficulties in stereoselective formation of the key alkylmetal intermediates. Here, we report an enantiodivergent strategy to efficiently achieve an array of synthetically useful chiral cyclopropanes, including chiral fluoroalkylated cyclopropanes and enantiomerically enriched cyclopropanes with chiral side chains, from racemic cyclopropylzinc reagents. This strategy relies on a one-pot, two-step enantiodivergent relay coupling process of the racemic cis-cyclopropylzinc reagents with two different electrophiles, which involves kinetic resolution of racemic cis-cyclopropylzinc reagents through a nickel-catalyzed enantioselective coupling with alkyl electrophiles, followed by a stereospecific relay coupling of the remaining enantiomeric cyclopropylzinc reagent with various electrophiles, to produce two types of functionalized chiral cyclopropanes with opposite configurations on the cyclopropane ring. These chiral cyclopropanes are versatile synthons for diverse transformations, rendering this strategy effective for obtaining structurally diversified molecules of medicinal interest.

ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR MODULATORS AND USES THEREOF

Disclosed are compounds of Formula (IVA), or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof: Formula (IVA), wherein "RIa", "RIb", "RIc", "RId", "RIe", are defined herein above, which compounds are believed suitable for use in positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR) receptors, for example, those found in the cerebral cortex and the hippocampus. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Alzheimer's disease (AD), schizophrenia, and Parkinson's disease (PD), or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease.

(HETERO)ARYL CYCLOPROPYLAMINE COMPOUNDS AS LSD1 INHIBITORS

The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula (I) as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.